Sclerostin
Evidence: B — Meaningful Human EvidenceEndocrine / Calcium-Bone Axis Signaling
Evidence Snapshot
What this grade covers
B reflects strong human GENETIC evidence (two primary discovery papers plus a 2024/2025 longitudinal follow-up) for sclerostin's role as a negative regulator of bone formation. This grade's strength comes entirely from natural-experiment/genetic evidence, not from any direct-administration or target-inhibitor-derived component. It does not cover any administered-sclerostin claim (not a real intervention class) or romosozumab's own efficacy/safety data, which remain product-specific.
Regulatory Context
Native sclerostin is an endogenous osteocyte-secreted protein with no approved product of its own; there is no rational therapeutic case for administering sclerostin. Romosozumab (Evenity) is an FDA-approved monoclonal antibody that blocks sclerostin, a separate, firewalled target-inhibition context.
Research Takeaway
Sclerostin (SOST gene product) is expressed exclusively by osteocytes and negatively regulates bone formation by inhibiting osteoblast differentiation and mineralization; this inhibitory action was shown not to occur via classical BMP antagonism.
Evidence boundary: Do not attach the specific Wnt/LRP5-LRP6 binding mechanism to this citation; that mechanism belongs to a separate, unfrozen paper.
See all 4 evidence claims →Quick Summary
Sclerostin is a bone-cell signaling protein that normally acts as a brake on new bone formation. Rare human genetic conditions where its absence causes very high bone density directly demonstrate its role; an approved antibody drug (romosozumab) blocks it to treat osteoporosis, but there is no established use for administering sclerostin itself.
Mechanism & Research Overview
Sclerostin is a bone-cell signaling protein that normally acts as a brake on new bone formation. Rare human genetic conditions where its absence causes very high bone density directly demonstrate its role; an approved antibody drug (romosozumab) blocks it to treat osteoporosis, but there is no established use for administering sclerostin itself.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Sclerostin (SOST gene product) is expressed exclusively by osteocytes and negatively regulates bone formation by inhibiting osteoblast differentiation and mineralization; this inhibitory action was shown not to occur via classical BMP antagonism.
Does not establish
Evidence boundary: Do not attach the specific Wnt/LRP5-LRP6 binding mechanism to this citation; that mechanism belongs to a separate, unfrozen paper.
Supported
A loss-of-function mutation in the SOST gene, encoding sclerostin, causes sclerosteosis, a rare human disorder of markedly increased bone density — direct human genetic evidence for sclerostin's role as a negative regulator of bone formation.
Does not establish
Evidence boundary: This paper's subject is sclerosteosis specifically; do not attribute it to Van Buchem disease.
Sources: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Supported
A 2025 longitudinal follow-up of adults with Van Buchem-disease-associated sclerostin deficiency documented sustained bone mineral density and clinical findings over long-term follow-up.
Supported
Romosozumab, a monoclonal antibody that binds and neutralizes sclerostin, is FDA-approved for osteoporosis and reduced fracture risk in the FRAME and ARCH trials.
Does not establish
Evidence boundary: This validates sclerostin's mechanistic role but is evidence about the drug, not about administering sclerostin itself. Romosozumab's boxed cardiovascular warning is specific to the drug/product, not to native sclerostin biology.
Sources: EVENITY (romosozumab-aqqg) — FDA Prescribing Information
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Romosozumab's FDA label carries a boxed warning against use in patients with MI/stroke in the preceding year; this is specific to the drug/product and must not be described as a risk of native sclerostin biology.Safety Consideration
Sclerosteosis and Van Buchem disease are both very rare; while scientifically clean natural-experiment evidence, the population size behind this evidence base is small.Safety Consideration
There is no rational therapeutic case for administering native sclerostin, which would suppress bone formation; this lane is structurally absent, not merely under-researched.
Research Areas Being Studied
Research areas discussed on this page reflect the Endocrine / Calcium-Bone Axis Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Long-term clinical and bone mineral density changes of adult patients with sclerostin deficiency due to van Buchem disease: a follow-up study (2025):
- Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) (2001):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Long-term clinical and bone mineral density changes of adult patients with sclerostin deficiency due to van Buchem disease: a follow-up study | 2025 | Longitudinal follow-up of adults with Van Buchem disease-associated sclerostin deficiency documenting sustained bone mineral density and clinical changes over long-term follow-up. | |||
| Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) | 2001 | A loss-of-function mutation in SOST, encoding sclerostin, causes sclerosteosis, a rare human disorder of markedly increased bone density — direct human genetic evidence for sclerostin as a negative regulator of bone formation. This paper's subject is sclerosteosis specifically, not Van Buchem disease. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| EVENITY (romosozumab-aqqg) — FDA Prescribing Information | Romosozumab is a monoclonal antibody that binds and neutralizes sclerostin, FDA-approved for osteoporosis; reduced fracture risk in the FRAME (placebo-controlled) and ARCH (active-comparator) pivotal trials. Carries a boxed cardiovascular warning (do not initiate in patients with MI/stroke in the preceding year) specific to the drug/product. TARGET_INHIBITION_CONTEXT: evidence about the antibody, never evidence of native-sclerostin administration efficacy or safety (there is no rational case for administering sclerostin). | No source link available |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and official regulatory information about Sclerostin and does not provide medical advice, an individualized treatment recommendation, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Sclerostin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.